{"gene":"GCK","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":1999,"finding":"Recombinant adenovirus-expressed human islet glucokinase (GCK) mutants E70K, V203A, and E300K show distinct kinetic defects in beta-HC9 cells: E70K has half the glucose affinity of wild-type; V203A shows decreased catalytic activity and 8-fold increase in glucose S0.5; E300K has near-normal glucose affinity but 10-fold reduced enzyme activity with markedly reduced protein levels (instability mutation); activating mutant V455M retains wild-type activity but has markedly reduced S0.5. These cell-biological effects on glucose-stimulated insulin release correlated with kinetic and expression data.","method":"Recombinant adenovirus transduction of beta-HC9 cells, kinetic analysis in vitro, Western blot, glucose-stimulated insulin secretion assay","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic reconstitution with multiple mutants, cell-based functional readout, Western blot for protein stability, single lab with orthogonal methods","pmids":["10455021"],"is_preprint":false},{"year":2006,"finding":"MODY2-associated GCK mutations impair enzyme function through distinct mechanisms: inserN161 fully inactivates GCK; M235V and R308W partially impair enzymatic activity; R397L leaves kinetics nearly unaffected. The R308W mutation causes protein instability and increases strength of interaction with glucokinase regulatory protein (GCKR/GKRP), as shown by pull-down assay. None of the mutations affected GCK interaction with PFKFB1.","method":"Recombinant protein expression, kinetic analysis, thermal stability assay, pull-down assay with GCKR and PFKFB1","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinetic reconstitution plus pull-down binding assays, multiple orthogonal methods, single lab","pmids":["17186219"],"is_preprint":false},{"year":2008,"finding":"Activating GCK mutations (S64Y, T65I, W99R, A456V) cluster at the allosteric activator site and cause congenital hyperinsulinism. The novel S64Y mutation markedly increases glucose affinity (S0.5 reduced from 7.39 to 1.49 mmol/l), yielding a relative activity index ~22-fold above wild-type.","method":"Kinetic characterization of recombinant mutant GCK proteins expressed in bacteria","journal":"European journal of endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinetic reconstitution of recombinant mutant proteins, multiple activating mutations characterized, single lab","pmids":["18450771"],"is_preprint":false},{"year":2008,"finding":"Age-related hypermethylation of CpG sites in the hepatic Gck promoter is negatively associated with Gck mRNA expression and GCK kinase activity in rats. Treatment of rat primary hepatocytes with the demethylating agent 5-aza-2'-deoxycytidine (5-Aza-CdR) caused a fourfold increase in Gck expression, establishing a causal link between promoter methylation and transcriptional repression.","method":"Bisulphite sequencing, real-time PCR, kinase activity assay, pharmacological demethylation (5-Aza-CdR) in primary hepatocytes","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 2 / Moderate — pharmacological intervention plus bisulphite sequencing plus activity assay, multiple orthogonal methods in one study","pmids":["18496667"],"is_preprint":false},{"year":2009,"finding":"Retinoids (retinol and retinal) synergize with insulin to induce hepatic Gck expression through activation of both RAR and RXR nuclear receptors, independently of SREBP-1c. Inhibition of RAR activation completely abolished the retinoid effect. Vitamin A deficiency in rats significantly reduced hepatic GCK specific activity and Gck mRNA, and intraperitoneal retinoic acid rescued Gck expression in VAD rats.","method":"Primary rat hepatocyte culture, real-time PCR, GCK activity assay, pharmacological inhibition of RAR/RXR, in vivo vitamin A deficiency/supplementation model in rats","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vitro and in vivo methods, pharmacological rescue, replicated in multiple rat models","pmids":["19173678"],"is_preprint":false},{"year":2012,"finding":"MODY2 GCK mutations S263P and G264S in the F260-L270 loop produce misfolded proteins with increased degradation rates and propensity to self-associate into SDS-resistant dimers and detergent-insoluble aggregates when stably expressed in HEK293 cells and MIN6 beta-cells. Protein quality control machinery (proteasomal/lysosomal) mediates their degradation. This establishes protein misfolding and aggregation as a disease mechanism for catalytically 'normal' GCK-MODY mutations.","method":"Stable overexpression in HEK293 and MIN6 cells, pulse-chase experiments, subcellular fractionation, SDS-PAGE for dimer detection","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 / Moderate — two cell lines, pulse-chase plus fractionation plus aggregation assays, multiple orthogonal methods, single lab","pmids":["22820548"],"is_preprint":false},{"year":2013,"finding":"The MODY2-associated GCK mutation R275C produces misfolded, unstable protein that forms dimers and aggregates when expressed in HEK293 cells and MIN6 beta-cells. Its degradation involves both lysosomal and proteasomal quality control systems. Mechanistically, the R275C substitution breaks a hydrogen bond between R275 and the carbonyl oxygen of D267, destabilizing the F260-L271 loop and promoting dimerization/aggregation.","method":"Stable expression in HEK293 and MIN6 cells, pulse-chase experiments, proteasome/lysosome inhibitor treatments, structural modelling","journal":"Molecular and cellular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — two cell lines, pharmacological pathway dissection, structural rationale, multiple orthogonal methods, single lab","pmids":["24001579"],"is_preprint":false},{"year":2014,"finding":"For homozygous GCK mutations causing neonatal/childhood-onset diabetes, protein thermostability (measured as relative stability index, RSI) is the primary determinant of clinical severity (r²=0.74, P=0.002), whereas kinetic defects alone do not correlate with phenotype (r²=0.05, P=0.39). Two later-onset homozygous mutations exhibited increased thermostability, consistent with this model.","method":"Recombinant mutant GCK protein expression, kinetic analysis, thermostability assay (differential scanning fluorimetry), clinical severity grading in 30 patients with 19 unique mutations","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — large case series (30 patients, 19 mutations), in vitro kinetics + thermostability with quantitative correlation to clinical phenotype, orthogonal methods","pmids":["25015100"],"is_preprint":false},{"year":2012,"finding":"Five MODY2 GCK missense mutations (p.Ile130Thr, p.Asp205His, p.Gly223Ser, p.His416Arg, p.Ala449Thr) impair GCK kinetic parameters. Notably, p.Ala449Thr (in the allosteric activator site) does not significantly reduce the activity index but dramatically alters glucose sensor parameters: Kcat is reduced ~15-fold while glucose affinity is increased ~6-fold (S0.5 = 1.33 vs 7.86 mM) with loss of cooperativity. Competitive inhibitor and allosteric activator experiments indicate this mutation alters the conformational equilibrium of GCK.","method":"Recombinant GST-GCK mutant protein expression in bacteria, kinetic analysis, competitive inhibitor and allosteric activator assays","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinetic reconstitution with mechanistic follow-up using inhibitors/activators, multiple orthogonal approaches, single lab","pmids":["22291974"],"is_preprint":false},{"year":2014,"finding":"A retinoic acid responsive element (RARE) in the hepatic Gck promoter interacts with RARα, RXRα, HNF4α, and COUP-TFII. Chromatin immunoprecipitation demonstrated that adenovirus-mediated overexpression of RARα, HNF4α, and COUP-TFII (but not RXRα) significantly increased their occupancy at the hepatic Gck promoter. Overexpression of RARα, HNF4α, and COUP-TFII (but not RXRα) affected RA- and insulin-mediated Gck expression in primary rat hepatocytes. Single nucleotide mutations in the RARE abolished promoter activation by retinoic acid.","method":"EMSA, ChIP assay, recombinant adenovirus overexpression, promoter mutagenesis, primary rat hepatocyte culture","journal":"The Journal of nutritional biochemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — EMSA + ChIP + functional promoter mutagenesis + overexpression, multiple orthogonal methods in primary cells, single lab","pmids":["24973045"],"is_preprint":false},{"year":2018,"finding":"Five novel GCK mutations (F195S, I211T, V222D, E236G, K458R) identified in Chinese MODY2 patients impair glucokinase through reduced catalytic efficiency and decreased thermostability. Additionally, interaction with glucokinase regulatory protein (GKRP) was significantly enhanced for I211T, I159V, T49N, and K458R; reduced for F195S and M381T; and completely abolished for A188T. V222D and E236G cause full inactivation via severe structural disruption.","method":"Recombinant protein expression, kinetic analysis, thermostability assay, GKRP interaction assay (pull-down)","journal":"Metabolism: clinical and experimental","confidence":"High","confidence_rationale":"Tier 1 / Moderate — kinetics, thermostability, and binding assays in one study across multiple mutations, single lab with orthogonal methods","pmids":["30257192"],"is_preprint":false},{"year":2020,"finding":"Nanosecond-timescale dynamics of human GCK were mapped using unnatural amino acid incorporation, time-resolved fluorescence, and 19F NMR. An intrinsically disordered loop within GCK samples multiple conformations in the unliganded state. Glucose binding and disease-associated mutations that suppress cooperativity alter the number and/or relative population of these conformational states, establishing nanosecond dynamics as part of the mechanism of GCK cooperativity.","method":"Unnatural amino acid incorporation, time-resolved fluorescence spectroscopy, 19F NMR spectroscopy","journal":"Biophysical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal biophysical methods (NMR + time-resolved fluorescence + unnatural AA), structural/dynamic characterization with functional validation via disease mutations","pmids":["32023434"],"is_preprint":false},{"year":2019,"finding":"Five GCK mutations (R43C, K169N, R191W, E221K, A379E) in Chinese MODY2 families show reduced enzyme activity with relative activity indexes of ~0.001–0.5 compared to wild-type (1.0), and decreased thermostability. For R250H and R275H variants, no significant difference in enzyme activity or thermal stability was detected compared to wild-type.","method":"Recombinant E. coli expression of mutant GCK, kinetic analysis, thermostability assay","journal":"Journal of diabetes investigation","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinetic reconstitution with thermostability, single lab, no additional orthogonal methods","pmids":["30592380"],"is_preprint":false},{"year":2021,"finding":"The novel gain-of-function GCK variant p.Val455Leu (V455L) significantly increases glucose affinity (S0.5: 2.4 vs 7.6 mmol/l wild-type) and shows additive susceptibility to both the endogenous activator fructose-2,6-bisphosphate and the synthetic allosteric activator RO-28-1675. GKRP binding is unimpaired for V455L, but reduced for V455M. Structural analyses implicated residue 455 in conformational rearrangements between inactive and active GCK states and in allosteric activation.","method":"Kinetic analysis of recombinant mutant GCK, allosteric activator/inhibitor assays, intracellular translocation assay, insulin secretion measurement, structural modelling","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinetics, functional cell assays, structural modelling, comparison of multiple variants, multiple orthogonal methods, single lab","pmids":["34532767"],"is_preprint":false},{"year":2024,"finding":"Hmbox1 functions as a transcriptional repressor of Gck in cardiomyocytes. Inhibition of Hmbox1 transcriptionally upregulates Gck, leading to improved mitochondrial respiration, glycolysis, reduced apoptosis, and cardioprotection after ischemia/reperfusion injury. ETS1 was identified as an upstream negative regulator of Hmbox1 transcription. These effects were confirmed by AAV9-mediated Hmbox1 knockdown and cardiomyocyte-specific Hmbox1 knockout in mice, with RNA sequencing, promoter prediction, and binding assays identifying Gck as a downstream effector.","method":"AAV9-mediated knockdown, cardiomyocyte-specific knockout (Cre-lox), RNA sequencing, promoter binding assays, Akt/mTOR/P70S6K pathway analysis, Seahorse metabolic assay, in vivo cardiac I/R injury model","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — two genetic loss-of-function approaches (KD and KO) with consistent phenotype, RNA-seq, binding assays, mechanistic pathway placement, single lab","pmids":["38708602"],"is_preprint":false},{"year":2021,"finding":"Silencing the Drosophila GCK orthologs Hex-A (expressed in insulin-producing cells) and Hex-C (expressed in fat body) results in MODY-2-like hyperglycemia. Hex-A is essential for insulin secretion, and Hex-A expression is required for Hex-C expression. Knockdown of either ortholog increases chromosome aberrations, reactive oxygen species, and advanced glycation end-products. Treatment with antioxidant vitamin B6 rescued chromosome aberrations, while a B6 inhibitor enhanced genomic instability, linking hyperglycemia-induced oxidative stress to DNA damage.","method":"Targeted RNAi knockdown in Drosophila, immunofluorescence for tissue expression, insulin secretion assay, ROS measurement, AGE quantification, chromosome aberration analysis, pharmacological rescue with vitamin B6","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ortholog functional studies in Drosophila with multiple readouts and pharmacological rescue; ortholog status well-supported but not mammalian GCK directly","pmids":["33477627"],"is_preprint":false},{"year":2008,"finding":"Biochemical characterization of six novel MODY2-associated GCK missense mutations (Y61S, V182L, C233R, E265K, A379V, K420E) shows all produce enzymes with reduced activity to varying degrees. C233R, affecting a critical active-site residue, renders GCK with undetectable enzymatic activity. Mutation severity correlates with structural changes at the mutated position.","method":"Recombinant mutant GCK expression, enzymatic activity assay","journal":"Journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinetic reconstitution, single lab, single method","pmids":["18322640"],"is_preprint":false}],"current_model":"Glucokinase (GCK) functions as the glucose sensor in pancreatic beta-cells by phosphorylating glucose to glucose-6-phosphate with sigmoidal kinetics (cooperative behavior) that sets the threshold for glucose-stimulated insulin secretion; its activity is allosterically regulated through conformational dynamics between inactive and active states, inhibited by glucokinase regulatory protein (GKRP) binding, and activated by endogenous fructose-2,6-bisphosphate and synthetic activators at a discrete allosteric site; disease-causing mutations impair function through reduced catalytic efficiency, decreased protein thermostability/misfolding leading to aggregation and proteasomal/lysosomal degradation, or enhanced GKRP interaction, while activating mutations increase glucose affinity and insulin secretion; in the liver, hepatic GCK expression is transcriptionally regulated by insulin and retinoids acting through a promoter RARE bound by RARα, HNF4α, and COUP-TFII, and is epigenetically suppressed by age-related promoter hypermethylation; in cardiomyocytes, GCK expression is repressed by Hmbox1 and its upregulation protects against ischemia/reperfusion injury via improved glucose metabolism."},"narrative":{"mechanistic_narrative":"Glucokinase (GCK) is a glucose-phosphorylating enzyme whose kinetic and conformational properties make it the rate-setting glucose sensor of pancreatic beta-cells and a key node in hepatic glucose metabolism [PMID:10455021, PMID:22291974]. Its function depends on an allosteric mechanism in which an intrinsically disordered loop samples multiple conformations on the nanosecond timescale; glucose binding and disease mutations reshape the population of these states to generate cooperative (sigmoidal) kinetics, and a discrete allosteric site couples to both the endogenous activator fructose-2,6-bisphosphate and synthetic activators such as RO-28-1675 [PMID:32023434, PMID:34532767]. Enzyme output is modulated by binding to glucokinase regulatory protein (GKRP), and mutations can either strengthen or abolish this interaction [PMID:17186219, PMID:30257192, PMID:34532767]. Disease-causing mutations act through three convergent routes: reduced catalytic efficiency, decreased thermostability that drives misfolding, dimerization, aggregation, and proteasomal/lysosomal degradation, or altered GKRP binding [PMID:22820548, PMID:24001579, PMID:30257192]; thermostability rather than kinetic defect alone is the principal determinant of clinical severity in homozygous, early-onset cases [PMID:25015100], whereas mutations at the allosteric activator site that increase glucose affinity cause congenital hyperinsulinism [PMID:18450771, PMID:34532767]. In the liver, GCK transcription is controlled by a promoter retinoic acid responsive element bound by RARalpha, HNF4alpha, and COUP-TFII, through which retinoids synergize with insulin to induce expression, and is epigenetically silenced by age-related promoter hypermethylation [PMID:18496667, PMID:19173678, PMID:24973045]. In cardiomyocytes GCK is repressed by the transcription factor Hmbox1, and its de-repression improves glucose metabolism and protects against ischemia/reperfusion injury [PMID:38708602].","teleology":[{"year":1999,"claim":"Established that distinct GCK point mutations produce mechanistically distinct defects, separating kinetic impairment from protein instability as causes of altered insulin secretion.","evidence":"Adenoviral expression of GCK mutants in beta-HC9 cells with in vitro kinetics, Western blot, and glucose-stimulated insulin secretion","pmids":["10455021"],"confidence":"High","gaps":["Did not resolve the structural basis of instability","Limited to a few mutants in one beta-cell line"]},{"year":2006,"claim":"Demonstrated that some MODY2 mutations impair function not by kinetics but by destabilizing protein and strengthening inhibitory GKRP binding, broadening the disease mechanism.","evidence":"Recombinant kinetics, thermal stability, and pull-down assays against GCKR and PFKFB1","pmids":["17186219"],"confidence":"High","gaps":["Physiological consequence of enhanced GKRP binding in vivo not shown","PFKFB1 interaction role left undefined"]},{"year":2008,"claim":"Localized activating mutations to a discrete allosteric activator site and linked increased glucose affinity to congenital hyperinsulinism.","evidence":"Kinetic characterization of recombinant activating GCK mutants","pmids":["18450771"],"confidence":"High","gaps":["Mechanism of conformational activation not resolved at this stage","No structural data on the activator site"]},{"year":2008,"claim":"Showed that hepatic Gck is epigenetically silenced by age-related promoter hypermethylation, providing a non-genetic mechanism of expression control.","evidence":"Bisulphite sequencing, qPCR, kinase activity assay, and 5-Aza-CdR demethylation in rat hepatocytes","pmids":["18496667"],"confidence":"High","gaps":["Methyltransferases responsible not identified","Rat liver only; human relevance not tested here"]},{"year":2008,"claim":"Expanded the catalog of catalytically impairing MODY2 mutations and correlated severity with active-site structural disruption.","evidence":"Recombinant expression and enzymatic activity assays for six novel mutations","pmids":["18322640"],"confidence":"Medium","gaps":["Single activity-assay method without orthogonal stability data","No cellular validation"]},{"year":2009,"claim":"Defined retinoids as insulin-synergizing inducers of hepatic Gck acting through RAR/RXR, independent of SREBP-1c.","evidence":"Primary rat hepatocytes, RAR/RXR pharmacological inhibition, and in vivo vitamin A deficiency/rescue","pmids":["19173678"],"confidence":"High","gaps":["Direct promoter element not yet mapped at this stage","Did not identify all cofactors"]},{"year":2012,"claim":"Identified protein misfolding, aggregation, and quality-control degradation as a disease mechanism for catalytically near-normal GCK-MODY mutations in the F260-L270 loop.","evidence":"Stable expression in HEK293 and MIN6 cells, pulse-chase, fractionation, and SDS-resistant dimer detection","pmids":["22820548"],"confidence":"High","gaps":["Aggregation behaviour in primary beta-cells not assessed","Chaperones mediating degradation not identified"]},{"year":2012,"claim":"Showed an allosteric-site mutation can reshape the glucose-sensor conformational equilibrium rather than simply lowering activity, linking mutations to conformational state.","evidence":"Recombinant kinetics with competitive inhibitor and allosteric activator probing","pmids":["22291974"],"confidence":"High","gaps":["Conformational states inferred indirectly, not directly observed","No structural snapshots"]},{"year":2013,"claim":"Provided an atomic-level rationale for misfolding by showing a single hydrogen-bond disruption destabilizes the F260-L271 loop to drive aggregation.","evidence":"Stable expression in HEK293/MIN6, pulse-chase, proteasome/lysosome inhibition, and structural modelling","pmids":["24001579"],"confidence":"High","gaps":["Modelled rather than experimentally determined structure of the mutant","Relative proteasome vs lysosome contribution not quantified"]},{"year":2014,"claim":"Established protein thermostability as the dominant determinant of clinical severity in homozygous early-onset disease, outweighing kinetic defects.","evidence":"Recombinant kinetics plus differential scanning fluorimetry correlated with clinical grading in 30 patients","pmids":["25015100"],"confidence":"High","gaps":["Correlation does not establish the in vivo degradation rate","Heterozygous phenotype predictors not addressed"]},{"year":2014,"claim":"Mapped the hepatic Gck RARE and its bound transcription factors, mechanistically anchoring retinoid/insulin regulation to specific cis and trans elements.","evidence":"EMSA, ChIP, adenoviral overexpression of RARalpha/HNF4alpha/COUP-TFII, and promoter mutagenesis in rat hepatocytes","pmids":["24973045"],"confidence":"High","gaps":["Human promoter not directly validated","RXRalpha occupancy role left unresolved"]},{"year":2018,"claim":"Integrated kinetics, thermostability, and GKRP-binding measurements across many mutations to show GKRP interaction can be variably enhanced, reduced, or abolished.","evidence":"Recombinant kinetics, thermostability, and GKRP pull-down for novel and known variants","pmids":["30257192"],"confidence":"High","gaps":["Cellular consequences of altered GKRP binding not tested","Structural basis of binding changes not resolved"]},{"year":2019,"claim":"Added quantitative kinetic and thermostability profiling of additional MODY2 variants, distinguishing functionally damaging from neutral substitutions.","evidence":"Recombinant E. coli expression with kinetic and thermostability assays","pmids":["30592380"],"confidence":"Medium","gaps":["No orthogonal cellular or binding assays","Variants R250H/R275H lacked a measurable defect, leaving pathogenicity unexplained"]},{"year":2020,"claim":"Directly demonstrated that nanosecond loop dynamics underlie GCK cooperativity, providing the physical mechanism of the glucose sensor.","evidence":"Unnatural amino acid incorporation, time-resolved fluorescence, and 19F NMR with disease-mutation validation","pmids":["32023434"],"confidence":"High","gaps":["Dynamics studied on isolated protein, not in cellular context","Coupling of dynamics to catalytic turnover not fully quantified"]},{"year":2021,"claim":"Linked a specific activating residue to conformational rearrangement and additive responsiveness to both endogenous and synthetic allosteric activators.","evidence":"Recombinant kinetics, allosteric activator/inhibitor assays, translocation and insulin secretion assays, and structural modelling of V455L vs V455M","pmids":["34532767"],"confidence":"High","gaps":["Structural mechanism modelled rather than directly determined","Long-term clinical consequences of the variant not addressed"]},{"year":2021,"claim":"Used Drosophila orthologs to connect GCK loss to MODY-like hyperglycemia and downstream oxidative DNA damage, extending function beyond enzyme kinetics to systemic genomic consequences.","evidence":"RNAi knockdown of Hex-A/Hex-C, insulin secretion, ROS/AGE quantification, chromosome aberration analysis, and vitamin B6 rescue","pmids":["33477627"],"confidence":"Medium","gaps":["Ortholog model, not mammalian GCK directly","Relevance of the genomic-instability axis to human disease untested"]},{"year":2024,"claim":"Identified Hmbox1 as a cardiomyocyte-specific transcriptional repressor of Gck and showed GCK de-repression is cardioprotective, defining a tissue role beyond beta-cell/liver glucose sensing.","evidence":"AAV9 knockdown and cardiomyocyte-specific knockout in mice, RNA-seq, promoter binding assays, Seahorse metabolism, and in vivo I/R injury model","pmids":["38708602"],"confidence":"High","gaps":["Direct Hmbox1 binding to the Gck promoter detail limited","Whether GCK alone is sufficient for protection not isolated"]},{"year":null,"claim":"How the structurally defined nanosecond dynamics, GKRP regulation, and tissue-specific transcriptional control are integrated to set glucose-sensing thresholds in vivo remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No in-cell or in-vivo measurement of GCK conformational dynamics","Human hepatic/cardiac transcriptional circuitry only partially mapped","Quantitative link between thermostability, degradation kinetics, and beta-cell function incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,8,16]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0,8]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,10,13]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[0,11,13]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5,6]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,4,14]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,4,9,14]}],"complexes":[],"partners":["GCKR","RARA","RXRA","HNF4A","COUP-TFII","HMBOX1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q12851","full_name":"Mitogen-activated protein kinase kinase kinase kinase 2","aliases":["B lymphocyte serine/threonine-protein kinase","Germinal center kinase","GC kinase","MAPK/ERK kinase kinase kinase 2","MEK kinase kinase 2","MEKKK 2","Rab8-interacting protein"],"length_aa":820,"mass_kda":91.6,"function":"Serine/threonine-protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Acts as a MAPK kinase kinase kinase (MAP4K) and is an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway and to a lesser extent of the p38 MAPKs signaling pathway. Required for the efficient activation of JNKs by TRAF6-dependent stimuli, including pathogen-associated molecular patterns (PAMPs) such as polyinosine-polycytidine (poly(IC)), lipopolysaccharides (LPS), lipid A, peptidoglycan (PGN), or bacterial flagellin. To a lesser degree, IL-1 and engagement of CD40 also stimulate MAP4K2-mediated JNKs activation. The requirement for MAP4K2/GCK is most pronounced for LPS signaling, and extends to LPS stimulation of c-Jun phosphorylation and induction of IL-8. Enhances MAP3K1 oligomerization, which may relieve N-terminal mediated MAP3K1 autoinhibition and lead to activation following autophosphorylation. Also mediates the SAP/JNK signaling pathway and the p38 MAPKs signaling pathway through activation of the MAP3Ks MAP3K10/MLK2 and MAP3K11/MLK3. May play a role in the regulation of vesicle targeting or fusion. regulation of vesicle targeting or fusion. Activator of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. MAP4Ks act in parallel to and are partially redundant with STK3/MST2 and STK4/MST2 in the phosphorylation and activation of LATS1/2, and establish MAP4Ks as components of the expanded Hippo pathway (PubMed:26437443)","subcellular_location":"Cytoplasm; Basolateral cell membrane; Golgi apparatus membrane","url":"https://www.uniprot.org/uniprotkb/Q12851/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GCK","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GCK","total_profiled":1310},"omim":[{"mim_id":"618858","title":"DIABETES MELLITUS, PERMANENT NEONATAL, 4; PNDM4","url":"https://www.omim.org/entry/618858"},{"mim_id":"618857","title":"DIABETES MELLITUS, PERMANENT NEONATAL, 3; PNDM3","url":"https://www.omim.org/entry/618857"},{"mim_id":"618856","title":"DIABETES MELLITUS, PERMANENT NEONATAL, 2; PNDM2","url":"https://www.omim.org/entry/618856"},{"mim_id":"616711","title":"TAO KINASE 3; TAOK3","url":"https://www.omim.org/entry/616711"},{"mim_id":"616511","title":"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 14; MODY14","url":"https://www.omim.org/entry/616511"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":12.4},{"tissue":"liver","ntpm":16.7},{"tissue":"pituitary gland","ntpm":19.5}],"url":"https://www.proteinatlas.org/search/GCK"},"hgnc":{"alias_symbol":["HK4","HKIV"],"prev_symbol":["MODY2"]},"alphafold":{"accession":"Q12851","domains":[{"cath_id":"3.30.200.20","chopping":"11-90","consensus_level":"high","plddt":87.4026,"start":11,"end":90},{"cath_id":"1.10.510.10","chopping":"95-289","consensus_level":"high","plddt":86.2157,"start":95,"end":289}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q12851","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q12851-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q12851-F1-predicted_aligned_error_v6.png","plddt_mean":74.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GCK","jax_strain_url":"https://www.jax.org/strain/search?query=GCK"},"sequence":{"accession":"Q12851","fasta_url":"https://rest.uniprot.org/uniprotkb/Q12851.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q12851/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q12851"}},"corpus_meta":[{"pmid":"19790256","id":"PMC_19790256","title":"Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia.","date":"2009","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19790256","citation_count":384,"is_preprint":false},{"pmid":"14517946","id":"PMC_14517946","title":"Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/14517946","citation_count":200,"is_preprint":false},{"pmid":"24323243","id":"PMC_24323243","title":"De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed.","date":"2013","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/24323243","citation_count":90,"is_preprint":false},{"pmid":"17573900","id":"PMC_17573900","title":"Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17573900","citation_count":81,"is_preprint":false},{"pmid":"11784851","id":"PMC_11784851","title":"Direct activation of mitogen-activated protein kinase kinase kinase MEKK1 by the Ste20p homologue GCK and the adapter protein TRAF2.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11784851","citation_count":78,"is_preprint":false},{"pmid":"36257325","id":"PMC_36257325","title":"Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts.","date":"2022","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36257325","citation_count":76,"is_preprint":false},{"pmid":"18496667","id":"PMC_18496667","title":"Hypermethylation of hepatic Gck promoter in ageing rats contributes to diabetogenic potential.","date":"2008","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/18496667","citation_count":66,"is_preprint":false},{"pmid":"27106716","id":"PMC_27106716","title":"GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated.","date":"2016","source":"Acta diabetologica","url":"https://pubmed.ncbi.nlm.nih.gov/27106716","citation_count":64,"is_preprint":false},{"pmid":"20628598","id":"PMC_20628598","title":"Common polymorphisms in MTNR1B, G6PC2 and GCK are associated with increased fasting plasma glucose and impaired beta-cell function in Chinese subjects.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20628598","citation_count":64,"is_preprint":false},{"pmid":"1740341","id":"PMC_1740341","title":"A polymorphic (CA)n repeat element maps the human glucokinase gene (GCK) to chromosome 7p.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1740341","citation_count":64,"is_preprint":false},{"pmid":"15102714","id":"PMC_15102714","title":"A series of maturity onset diabetes of the young, type 2 (MODY2) mouse models generated by a large-scale ENU mutagenesis program.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15102714","citation_count":63,"is_preprint":false},{"pmid":"19241058","id":"PMC_19241058","title":"Association of GCKR rs780094, alone or in combination with GCK rs1799884, with type 2 diabetes and related traits in a Han Chinese population.","date":"2009","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/19241058","citation_count":63,"is_preprint":false},{"pmid":"18450771","id":"PMC_18450771","title":"Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation.","date":"2008","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18450771","citation_count":63,"is_preprint":false},{"pmid":"19073768","id":"PMC_19073768","title":"Interaction effect of genetic polymorphisms in glucokinase (GCK) and glucokinase regulatory protein (GCKR) on metabolic traits in healthy Chinese adults and adolescents.","date":"2008","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/19073768","citation_count":58,"is_preprint":false},{"pmid":"19533084","id":"PMC_19533084","title":"Combined effects of single-nucleotide polymorphisms in GCK, GCKR, G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk.","date":"2009","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/19533084","citation_count":58,"is_preprint":false},{"pmid":"15684092","id":"PMC_15684092","title":"GCK-3, a newly identified Ste20 kinase, binds to and regulates the activity of a cell cycle-dependent ClC anion channel.","date":"2005","source":"The Journal of general physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15684092","citation_count":55,"is_preprint":false},{"pmid":"17828387","id":"PMC_17828387","title":"Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young.","date":"2007","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/17828387","citation_count":54,"is_preprint":false},{"pmid":"18411240","id":"PMC_18411240","title":"Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2).","date":"2008","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/18411240","citation_count":54,"is_preprint":false},{"pmid":"38708602","id":"PMC_38708602","title":"Inhibition of Hmbox1 Promotes Cardiomyocyte Survival and Glucose Metabolism Through Gck Activation in Ischemia/Reperfusion Injury.","date":"2024","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/38708602","citation_count":52,"is_preprint":false},{"pmid":"9788432","id":"PMC_9788432","title":"The germinal center kinase (GCK)-related protein kinases HPK1 and KHS are candidates for highly selective signal transducers of Crk family adapter proteins.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9788432","citation_count":51,"is_preprint":false},{"pmid":"21178429","id":"PMC_21178429","title":"The fatty acid synthase fasn-1 acts upstream of WNK and Ste20/GCK-VI kinases to modulate antimicrobial peptide expression in C. elegans epidermis.","date":"2010","source":"Virulence","url":"https://pubmed.ncbi.nlm.nih.gov/21178429","citation_count":50,"is_preprint":false},{"pmid":"17186219","id":"PMC_17186219","title":"Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity.","date":"2006","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/17186219","citation_count":49,"is_preprint":false},{"pmid":"17127342","id":"PMC_17127342","title":"The GCK II and III subfamilies of the STE20 group kinases.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17127342","citation_count":46,"is_preprint":false},{"pmid":"25015100","id":"PMC_25015100","title":"Phenotypic severity of homozygous GCK mutations causing neonatal or childhood-onset diabetes is primarily mediated through effects on protein stability.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25015100","citation_count":45,"is_preprint":false},{"pmid":"18399931","id":"PMC_18399931","title":"Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry.","date":"2008","source":"Pediatric diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/18399931","citation_count":44,"is_preprint":false},{"pmid":"10990085","id":"PMC_10990085","title":"Maternal diabetes alters birth weight in glucokinase-deficient (MODY2) kindred but has no influence on adult weight, height, insulin secretion or insulin sensitivity.","date":"2000","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/10990085","citation_count":44,"is_preprint":false},{"pmid":"10455021","id":"PMC_10455021","title":"Cell-biological assessment of human glucokinase mutants causing maturity-onset diabetes of the young type 2 (MODY-2) or glucokinase-linked hyperinsulinaemia (GK-HI).","date":"1999","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/10455021","citation_count":42,"is_preprint":false},{"pmid":"22761713","id":"PMC_22761713","title":"Glucokinase (GCK) mutations and their characterization in MODY2 children of southern Italy.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22761713","citation_count":37,"is_preprint":false},{"pmid":"23139355","id":"PMC_23139355","title":"Metabolite profiling reveals normal metabolic control in carriers of mutations in the glucokinase gene (MODY2).","date":"2012","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/23139355","citation_count":37,"is_preprint":false},{"pmid":"19903754","id":"PMC_19903754","title":"Clinical heterogeneity in monogenic diabetes caused by mutations in the glucokinase gene (GCK-MODY).","date":"2009","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/19903754","citation_count":37,"is_preprint":false},{"pmid":"24549415","id":"PMC_24549415","title":"Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level.","date":"2014","source":"Acta diabetologica","url":"https://pubmed.ncbi.nlm.nih.gov/24549415","citation_count":37,"is_preprint":false},{"pmid":"39245718","id":"PMC_39245718","title":"Glucokinase (GCK) in diabetes: from molecular mechanisms to disease pathogenesis.","date":"2024","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/39245718","citation_count":36,"is_preprint":false},{"pmid":"30535721","id":"PMC_30535721","title":"Management and pregnancy outcomes of women with GCK-MODY enrolled in the US Monogenic Diabetes Registry.","date":"2018","source":"Acta diabetologica","url":"https://pubmed.ncbi.nlm.nih.gov/30535721","citation_count":36,"is_preprint":false},{"pmid":"19173678","id":"PMC_19173678","title":"Retinoids synergize with insulin to induce hepatic Gck expression.","date":"2009","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19173678","citation_count":35,"is_preprint":false},{"pmid":"12966093","id":"PMC_12966093","title":"The direct activation of MIK, a germinal center kinase (GCK)-like kinase, by MARK, a maize atypical receptor kinase, suggests a new mechanism for signaling through kinase-dead receptors.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12966093","citation_count":35,"is_preprint":false},{"pmid":"24696842","id":"PMC_24696842","title":"GCK gene-body hypomethylation is associated with the risk of coronary heart disease.","date":"2014","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/24696842","citation_count":34,"is_preprint":false},{"pmid":"10702802","id":"PMC_10702802","title":"Role of TRAF2/GCK in melanoma sensitivity to UV-induced apoptosis.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10702802","citation_count":33,"is_preprint":false},{"pmid":"11440371","id":"PMC_11440371","title":"Routine mutation screening of HNF-1alpha and GCK genes in MODY diagnosis: how effective are the techniques of DHPLC and direct sequencing used in combination?","date":"2001","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/11440371","citation_count":33,"is_preprint":false},{"pmid":"28359772","id":"PMC_28359772","title":"GCK, GCKR, FADS1, DGKB/TMEM195 and CDKAL1 Gene Polymorphisms in Women with Gestational Diabetes.","date":"2017","source":"Canadian journal of diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/28359772","citation_count":31,"is_preprint":false},{"pmid":"15731009","id":"PMC_15731009","title":"Ste20/GCK kinase Nak1/Orb3 polarizes the actin cytoskeleton in fission yeast during the cell cycle.","date":"2005","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15731009","citation_count":31,"is_preprint":false},{"pmid":"33318207","id":"PMC_33318207","title":"Inhibition of GCK-IV kinases dissociates cell death and axon regeneration in CNS neurons.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33318207","citation_count":30,"is_preprint":false},{"pmid":"24244580","id":"PMC_24244580","title":"Identification of candidate children for maturity-onset diabetes of the young type 2 (MODY2) gene testing: a seven-item clinical flowchart (7-iF).","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24244580","citation_count":29,"is_preprint":false},{"pmid":"19884385","id":"PMC_19884385","title":"Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene.","date":"2009","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19884385","citation_count":29,"is_preprint":false},{"pmid":"24992032","id":"PMC_24992032","title":"Elevated CpG island methylation of GCK gene predicts the risk of type 2 diabetes in Chinese males.","date":"2014","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/24992032","citation_count":28,"is_preprint":false},{"pmid":"18248649","id":"PMC_18248649","title":"Haploinsufficiency at GCK gene is not a frequent event in MODY2 patients.","date":"2008","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18248649","citation_count":27,"is_preprint":false},{"pmid":"33129248","id":"PMC_33129248","title":"Clinical implications of the glucokinase impaired function - GCK MODY today.","date":"2020","source":"Physiological research","url":"https://pubmed.ncbi.nlm.nih.gov/33129248","citation_count":27,"is_preprint":false},{"pmid":"21647250","id":"PMC_21647250","title":"Berberine regulated Gck, G6pc, Pck1 and Srebp-1c expression and activated AMP-activated protein kinase in primary rat hepatocytes.","date":"2011","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21647250","citation_count":27,"is_preprint":false},{"pmid":"19018513","id":"PMC_19018513","title":"The association of common genetic variants in the APOA5, LPL and GCK genes with longitudinal changes in metabolic and cardiovascular traits.","date":"2008","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/19018513","citation_count":27,"is_preprint":false},{"pmid":"24804978","id":"PMC_24804978","title":"Molecular and clinical characterization of glucokinase maturity-onset diabetes of the young (GCK-MODY) in Japanese patients.","date":"2014","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/24804978","citation_count":25,"is_preprint":false},{"pmid":"22517333","id":"PMC_22517333","title":"Associations of apolipoprotein A5 (APOA5), glucokinase (GCK) and glucokinase regulatory protein (GCKR) polymorphisms and lifestyle factors with the risk of dyslipidemia and dysglycemia in Japanese - a cross-sectional data from the J-MICC Study.","date":"2012","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/22517333","citation_count":25,"is_preprint":false},{"pmid":"22291974","id":"PMC_22291974","title":"Functional characterization of MODY2 mutations highlights the importance of the fine-tuning of glucokinase and its role in glucose sensing.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22291974","citation_count":22,"is_preprint":false},{"pmid":"30012560","id":"PMC_30012560","title":"A Hippo Pathway-Related GCK Controls Both Sexual and Vegetative Developmental Processes in the Fungus Sordaria macrospora.","date":"2018","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30012560","citation_count":21,"is_preprint":false},{"pmid":"25892191","id":"PMC_25892191","title":"Aberrant methylation of the GCK gene body is associated with the risk of essential hypertension.","date":"2015","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/25892191","citation_count":21,"is_preprint":false},{"pmid":"30592380","id":"PMC_30592380","title":"Identification and functional analysis of GCK gene mutations in 12 Chinese families with hyperglycemia.","date":"2019","source":"Journal of diabetes investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30592380","citation_count":20,"is_preprint":false},{"pmid":"33450726","id":"PMC_33450726","title":"Localized increases in CEPT1 and ATGL elevate plasmalogen phosphatidylcholines in HDLs contributing to atheroprotective lipid profiles in hyperglycemic GCK-MODY.","date":"2021","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/33450726","citation_count":20,"is_preprint":false},{"pmid":"25987348","id":"PMC_25987348","title":"Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.","date":"2015","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/25987348","citation_count":20,"is_preprint":false},{"pmid":"31882596","id":"PMC_31882596","title":"Chronic heavy alcohol consumption influences the association between genetic variants of GCK or INSR and the development of diabetes in men: A 12-year follow-up study.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31882596","citation_count":19,"is_preprint":false},{"pmid":"15841481","id":"PMC_15841481","title":"Identification of novel GCK and HNF1A/TCF1 mutations and polymorphisms in German families with maturity-onset diabetes of the young (MODY).","date":"2005","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/15841481","citation_count":19,"is_preprint":false},{"pmid":"31720743","id":"PMC_31720743","title":"Genetic deletion of a short fragment of glucokinase in rabbit by CRISPR/Cas9 leading to hyperglycemia and other typical features seen in MODY-2.","date":"2019","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/31720743","citation_count":19,"is_preprint":false},{"pmid":"35293603","id":"PMC_35293603","title":"Potential impact of GCK, MIR-196A-2 and MIR-423 gene abnormalities on the development and progression of type 2 diabetes mellitus in Asir and Tabuk regions of Saudi Arabia.","date":"2022","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/35293603","citation_count":18,"is_preprint":false},{"pmid":"27256595","id":"PMC_27256595","title":"GCK gene mutations are a common cause of childhood-onset MODY (maturity-onset diabetes of the young) in Turkey.","date":"2016","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27256595","citation_count":18,"is_preprint":false},{"pmid":"12442280","id":"PMC_12442280","title":"GCK and HNF1A mutations in Canadian families with maturity onset diabetes of the young (MODY).","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12442280","citation_count":18,"is_preprint":false},{"pmid":"33036022","id":"PMC_33036022","title":"Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33036022","citation_count":17,"is_preprint":false},{"pmid":"19246396","id":"PMC_19246396","title":"GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19246396","citation_count":17,"is_preprint":false},{"pmid":"24973045","id":"PMC_24973045","title":"A RARE of hepatic Gck promoter interacts with RARα, HNF4α and COUP-TFII that affect retinoic acid- and insulin-induced Gck expression.","date":"2014","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24973045","citation_count":17,"is_preprint":false},{"pmid":"29510678","id":"PMC_29510678","title":"Genetic and clinical characteristics of Chinese children with Glucokinase-maturity-onset diabetes of the young (GCK-MODY).","date":"2018","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/29510678","citation_count":17,"is_preprint":false},{"pmid":"9931402","id":"PMC_9931402","title":"Molecular characterisation of plant cDNAs BnMAP4Kalpha1 and BnMAP4Kalpha2 belonging to the GCK/SPS1 subfamily of MAP kinase kinase kinase kinase.","date":"1999","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9931402","citation_count":17,"is_preprint":false},{"pmid":"28170077","id":"PMC_28170077","title":"Clinical application of ACMG-AMP guidelines in HNF1A and GCK variants in a cohort of MODY families.","date":"2017","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28170077","citation_count":17,"is_preprint":false},{"pmid":"15305805","id":"PMC_15305805","title":"Spectrum of HNF1A and GCK mutations in Canadian families with maturity-onset diabetes of the young (MODY).","date":"2004","source":"Clinical and investigative medicine. Medecine clinique et experimentale","url":"https://pubmed.ncbi.nlm.nih.gov/15305805","citation_count":17,"is_preprint":false},{"pmid":"30257192","id":"PMC_30257192","title":"Insights into pathogenesis of five novel GCK mutations identified in Chinese MODY patients.","date":"2018","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/30257192","citation_count":16,"is_preprint":false},{"pmid":"26240958","id":"PMC_26240958","title":"Prevalence of Retinopathy in Adult Patients with GCK-MODY and HNF1A-MODY.","date":"2015","source":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","url":"https://pubmed.ncbi.nlm.nih.gov/26240958","citation_count":15,"is_preprint":false},{"pmid":"30063936","id":"PMC_30063936","title":"Association of Native American ancestry and common variants in ACE, ADIPOR2, MTNR1B, GCK, TCF7L2 and FTO genes with glycemic traits in Colombian population.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30063936","citation_count":15,"is_preprint":false},{"pmid":"31214998","id":"PMC_31214998","title":"Using Clinical Indices to Distinguish MODY2 (GCK Mutation) and MODY3 (HNF1A Mutation) from Type 1 Diabetes in a Young Chinese Population.","date":"2019","source":"Diabetes therapy : research, treatment and education of diabetes and related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/31214998","citation_count":14,"is_preprint":false},{"pmid":"22820548","id":"PMC_22820548","title":"GCK-MODY diabetes associated with protein misfolding, cellular self-association and degradation.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22820548","citation_count":14,"is_preprint":false},{"pmid":"32023434","id":"PMC_32023434","title":"Nanosecond-Timescale Dynamics and Conformational Heterogeneity in Human GCK Regulation and Disease.","date":"2020","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/32023434","citation_count":14,"is_preprint":false},{"pmid":"24535998","id":"PMC_24535998","title":"GCK, GCKR polymorphisms and risk of chronic kidney disease in Japanese individuals: data from the J-MICC Study.","date":"2013","source":"Journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/24535998","citation_count":14,"is_preprint":false},{"pmid":"23009393","id":"PMC_23009393","title":"Co-inheritance of HNF1a and GCK mutations in a family with maturity-onset diabetes of the young (MODY): implications for genetic testing.","date":"2013","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23009393","citation_count":14,"is_preprint":false},{"pmid":"29056535","id":"PMC_29056535","title":"Analysis of the GCK gene in 79 MODY type 2 patients: A multicenter Turkish study, mutation profile and description of twenty novel mutations.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/29056535","citation_count":14,"is_preprint":false},{"pmid":"25501962","id":"PMC_25501962","title":"Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients.","date":"2014","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25501962","citation_count":13,"is_preprint":false},{"pmid":"33277730","id":"PMC_33277730","title":"Evaluation of pregnancy outcomes in women with GCK-MODY.","date":"2021","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/33277730","citation_count":13,"is_preprint":false},{"pmid":"31968686","id":"PMC_31968686","title":"Maturity-Onset Diabetes of the Young (MODY) in Portugal: Novel GCK, HNFA1 and HNFA4 Mutations.","date":"2020","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31968686","citation_count":13,"is_preprint":false},{"pmid":"18322640","id":"PMC_18322640","title":"Biochemical characterization of novel glucokinase mutations isolated from Spanish maturity-onset diabetes of the young (MODY2) patients.","date":"2008","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18322640","citation_count":13,"is_preprint":false},{"pmid":"19282865","id":"PMC_19282865","title":"Association of polymorphisms of SORBS1, GCK and WISP1 with hypertension in community-dwelling Japanese individuals.","date":"2009","source":"Hypertension research : official journal of the Japanese Society of Hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/19282865","citation_count":13,"is_preprint":false},{"pmid":"23890519","id":"PMC_23890519","title":"A report of 2 new cases of MODY2 and review of the literature: implications in the search for type 2 diabetes drugs.","date":"2013","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/23890519","citation_count":12,"is_preprint":false},{"pmid":"21688019","id":"PMC_21688019","title":"The coexistence of type 1 diabetes, MODY2 and metabolic syndrome in a young girl.","date":"2011","source":"Acta diabetologica","url":"https://pubmed.ncbi.nlm.nih.gov/21688019","citation_count":12,"is_preprint":false},{"pmid":"20595048","id":"PMC_20595048","title":"The Caenorhabditis elegans Ste20 kinase, GCK-3, is essential for postembryonic developmental timing and regulates meiotic chromosome segregation.","date":"2010","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20595048","citation_count":12,"is_preprint":false},{"pmid":"19826475","id":"PMC_19826475","title":"The germinal center kinase GCK-1 is a negative regulator of MAP kinase activation and apoptosis in the C. elegans germline.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19826475","citation_count":12,"is_preprint":false},{"pmid":"25008049","id":"PMC_25008049","title":"Mutational analysis of ABCC8, KCNJ11, GLUD1, HNF4A and GCK genes in 30 Chinese patients with congenital hyperinsulinism.","date":"2014","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/25008049","citation_count":12,"is_preprint":false},{"pmid":"32375122","id":"PMC_32375122","title":"MODY2 in Asia: analysis of GCK mutations and clinical characteristics.","date":"2020","source":"Endocrine connections","url":"https://pubmed.ncbi.nlm.nih.gov/32375122","citation_count":11,"is_preprint":false},{"pmid":"24001579","id":"PMC_24001579","title":"GCK-MODY diabetes as a protein misfolding disease: the mutation R275C promotes protein misfolding, self-association and cellular degradation.","date":"2013","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24001579","citation_count":11,"is_preprint":false},{"pmid":"34532767","id":"PMC_34532767","title":"The novel GCK variant p.Val455Leu associated with hyperinsulinism is susceptible to allosteric activation and is conducive to weight gain and the development of diabetes.","date":"2021","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/34532767","citation_count":11,"is_preprint":false},{"pmid":"28867816","id":"PMC_28867816","title":"Dairy Product Consumption Interacts with Glucokinase (GCK) Gene Polymorphisms Associated with Insulin Resistance.","date":"2017","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28867816","citation_count":11,"is_preprint":false},{"pmid":"33812904","id":"PMC_33812904","title":"Maturity onset diabetes of the young type 2 (MODY2): Insight from an extended family.","date":"2021","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/33812904","citation_count":10,"is_preprint":false},{"pmid":"33477627","id":"PMC_33477627","title":"Functional Inactivation of Drosophila GCK Orthologs Causes Genomic Instability and Oxidative Stress in a Fly Model of MODY-2.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33477627","citation_count":10,"is_preprint":false},{"pmid":"16026363","id":"PMC_16026363","title":"Clinical characteristics of mutation carriers in a large family with glucokinase diabetes (MODY2).","date":"2005","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/16026363","citation_count":10,"is_preprint":false},{"pmid":"35674212","id":"PMC_35674212","title":"Localized islet nuclear enlargement hyperinsulinism (LINE-HI) due to ABCC8 and GCK mosaic mutations.","date":"2022","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35674212","citation_count":10,"is_preprint":false},{"pmid":"16897489","id":"PMC_16897489","title":"Regulation of the kinase activity of the MIK GCK-like MAP4K by alternative splicing.","date":"2006","source":"Plant molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16897489","citation_count":10,"is_preprint":false},{"pmid":"34406393","id":"PMC_34406393","title":"Sequencing Cell-free Fetal DNA in Pregnant Women With GCK-MODY.","date":"2021","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34406393","citation_count":9,"is_preprint":false},{"pmid":"35229243","id":"PMC_35229243","title":"Identification and management of GCK-MODY complicating pregnancy in Chinese patients with gestational diabetes.","date":"2022","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35229243","citation_count":9,"is_preprint":false},{"pmid":"31605429","id":"PMC_31605429","title":"Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients.","date":"2019","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/31605429","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55261,"output_tokens":5444,"usd":0.123721,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13329,"output_tokens":4689,"usd":0.091935,"stage2_stop_reason":"end_turn"},"total_usd":0.215656,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"Looking at the corpus, I need to carefully distinguish between:\n1. **GCK = Glucokinase** (the metabolic enzyme, HGNC gene symbol GCK / MODY2 / HKIV) — canonical target\n2. **GCK = Germinal Center Kinase** (MAP4K2, a Ste20-family kinase) — **different gene**, alias collision\n3. **GCK-3, GCK-1** in C. elegans — these are Ste20/GCK-VI subfamily kinases, not orthologs of human glucokinase\n4. Plant GCK/MIK proteins — symbol collision, exclude\n\nThe query gene is **GCK (glucokinase, HKIV, MODY2)**. Papers about \"germinal center kinase\" (MAP4K2) are a **different human gene** sharing the GCK abbreviation — these must be excluded (PMIDs: 11784851, 9788432, 10702802, 19246396, 33036022, 17127342, 33318207). C. elegans GCK-3, GCK-1 papers (15684092, 21178429, 20595048, 19826475) are about Ste20-VI subfamily kinases unrelated to glucokinase. Plant MIK/BnMAP4K papers (12966093, 9931402, 30012560, 16897489) are symbol collisions. Drosophila Hex-A/Hex-C paper (33477627) describes glucokinase orthologs — include.\n\nNow extracting mechanistic discoveries for human glucokinase (GCK):\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"Recombinant adenovirus-expressed human islet glucokinase (GCK) mutants E70K, V203A, and E300K show distinct kinetic defects in beta-HC9 cells: E70K has half the glucose affinity of wild-type; V203A shows decreased catalytic activity and 8-fold increase in glucose S0.5; E300K has near-normal glucose affinity but 10-fold reduced enzyme activity with markedly reduced protein levels (instability mutation); activating mutant V455M retains wild-type activity but has markedly reduced S0.5. These cell-biological effects on glucose-stimulated insulin release correlated with kinetic and expression data.\",\n      \"method\": \"Recombinant adenovirus transduction of beta-HC9 cells, kinetic analysis in vitro, Western blot, glucose-stimulated insulin secretion assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic reconstitution with multiple mutants, cell-based functional readout, Western blot for protein stability, single lab with orthogonal methods\",\n      \"pmids\": [\"10455021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MODY2-associated GCK mutations impair enzyme function through distinct mechanisms: inserN161 fully inactivates GCK; M235V and R308W partially impair enzymatic activity; R397L leaves kinetics nearly unaffected. The R308W mutation causes protein instability and increases strength of interaction with glucokinase regulatory protein (GCKR/GKRP), as shown by pull-down assay. None of the mutations affected GCK interaction with PFKFB1.\",\n      \"method\": \"Recombinant protein expression, kinetic analysis, thermal stability assay, pull-down assay with GCKR and PFKFB1\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinetic reconstitution plus pull-down binding assays, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"17186219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Activating GCK mutations (S64Y, T65I, W99R, A456V) cluster at the allosteric activator site and cause congenital hyperinsulinism. The novel S64Y mutation markedly increases glucose affinity (S0.5 reduced from 7.39 to 1.49 mmol/l), yielding a relative activity index ~22-fold above wild-type.\",\n      \"method\": \"Kinetic characterization of recombinant mutant GCK proteins expressed in bacteria\",\n      \"journal\": \"European journal of endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinetic reconstitution of recombinant mutant proteins, multiple activating mutations characterized, single lab\",\n      \"pmids\": [\"18450771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Age-related hypermethylation of CpG sites in the hepatic Gck promoter is negatively associated with Gck mRNA expression and GCK kinase activity in rats. Treatment of rat primary hepatocytes with the demethylating agent 5-aza-2'-deoxycytidine (5-Aza-CdR) caused a fourfold increase in Gck expression, establishing a causal link between promoter methylation and transcriptional repression.\",\n      \"method\": \"Bisulphite sequencing, real-time PCR, kinase activity assay, pharmacological demethylation (5-Aza-CdR) in primary hepatocytes\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological intervention plus bisulphite sequencing plus activity assay, multiple orthogonal methods in one study\",\n      \"pmids\": [\"18496667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Retinoids (retinol and retinal) synergize with insulin to induce hepatic Gck expression through activation of both RAR and RXR nuclear receptors, independently of SREBP-1c. Inhibition of RAR activation completely abolished the retinoid effect. Vitamin A deficiency in rats significantly reduced hepatic GCK specific activity and Gck mRNA, and intraperitoneal retinoic acid rescued Gck expression in VAD rats.\",\n      \"method\": \"Primary rat hepatocyte culture, real-time PCR, GCK activity assay, pharmacological inhibition of RAR/RXR, in vivo vitamin A deficiency/supplementation model in rats\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vitro and in vivo methods, pharmacological rescue, replicated in multiple rat models\",\n      \"pmids\": [\"19173678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MODY2 GCK mutations S263P and G264S in the F260-L270 loop produce misfolded proteins with increased degradation rates and propensity to self-associate into SDS-resistant dimers and detergent-insoluble aggregates when stably expressed in HEK293 cells and MIN6 beta-cells. Protein quality control machinery (proteasomal/lysosomal) mediates their degradation. This establishes protein misfolding and aggregation as a disease mechanism for catalytically 'normal' GCK-MODY mutations.\",\n      \"method\": \"Stable overexpression in HEK293 and MIN6 cells, pulse-chase experiments, subcellular fractionation, SDS-PAGE for dimer detection\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two cell lines, pulse-chase plus fractionation plus aggregation assays, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"22820548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The MODY2-associated GCK mutation R275C produces misfolded, unstable protein that forms dimers and aggregates when expressed in HEK293 cells and MIN6 beta-cells. Its degradation involves both lysosomal and proteasomal quality control systems. Mechanistically, the R275C substitution breaks a hydrogen bond between R275 and the carbonyl oxygen of D267, destabilizing the F260-L271 loop and promoting dimerization/aggregation.\",\n      \"method\": \"Stable expression in HEK293 and MIN6 cells, pulse-chase experiments, proteasome/lysosome inhibitor treatments, structural modelling\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two cell lines, pharmacological pathway dissection, structural rationale, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"24001579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"For homozygous GCK mutations causing neonatal/childhood-onset diabetes, protein thermostability (measured as relative stability index, RSI) is the primary determinant of clinical severity (r²=0.74, P=0.002), whereas kinetic defects alone do not correlate with phenotype (r²=0.05, P=0.39). Two later-onset homozygous mutations exhibited increased thermostability, consistent with this model.\",\n      \"method\": \"Recombinant mutant GCK protein expression, kinetic analysis, thermostability assay (differential scanning fluorimetry), clinical severity grading in 30 patients with 19 unique mutations\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — large case series (30 patients, 19 mutations), in vitro kinetics + thermostability with quantitative correlation to clinical phenotype, orthogonal methods\",\n      \"pmids\": [\"25015100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Five MODY2 GCK missense mutations (p.Ile130Thr, p.Asp205His, p.Gly223Ser, p.His416Arg, p.Ala449Thr) impair GCK kinetic parameters. Notably, p.Ala449Thr (in the allosteric activator site) does not significantly reduce the activity index but dramatically alters glucose sensor parameters: Kcat is reduced ~15-fold while glucose affinity is increased ~6-fold (S0.5 = 1.33 vs 7.86 mM) with loss of cooperativity. Competitive inhibitor and allosteric activator experiments indicate this mutation alters the conformational equilibrium of GCK.\",\n      \"method\": \"Recombinant GST-GCK mutant protein expression in bacteria, kinetic analysis, competitive inhibitor and allosteric activator assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinetic reconstitution with mechanistic follow-up using inhibitors/activators, multiple orthogonal approaches, single lab\",\n      \"pmids\": [\"22291974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A retinoic acid responsive element (RARE) in the hepatic Gck promoter interacts with RARα, RXRα, HNF4α, and COUP-TFII. Chromatin immunoprecipitation demonstrated that adenovirus-mediated overexpression of RARα, HNF4α, and COUP-TFII (but not RXRα) significantly increased their occupancy at the hepatic Gck promoter. Overexpression of RARα, HNF4α, and COUP-TFII (but not RXRα) affected RA- and insulin-mediated Gck expression in primary rat hepatocytes. Single nucleotide mutations in the RARE abolished promoter activation by retinoic acid.\",\n      \"method\": \"EMSA, ChIP assay, recombinant adenovirus overexpression, promoter mutagenesis, primary rat hepatocyte culture\",\n      \"journal\": \"The Journal of nutritional biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — EMSA + ChIP + functional promoter mutagenesis + overexpression, multiple orthogonal methods in primary cells, single lab\",\n      \"pmids\": [\"24973045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Five novel GCK mutations (F195S, I211T, V222D, E236G, K458R) identified in Chinese MODY2 patients impair glucokinase through reduced catalytic efficiency and decreased thermostability. Additionally, interaction with glucokinase regulatory protein (GKRP) was significantly enhanced for I211T, I159V, T49N, and K458R; reduced for F195S and M381T; and completely abolished for A188T. V222D and E236G cause full inactivation via severe structural disruption.\",\n      \"method\": \"Recombinant protein expression, kinetic analysis, thermostability assay, GKRP interaction assay (pull-down)\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — kinetics, thermostability, and binding assays in one study across multiple mutations, single lab with orthogonal methods\",\n      \"pmids\": [\"30257192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Nanosecond-timescale dynamics of human GCK were mapped using unnatural amino acid incorporation, time-resolved fluorescence, and 19F NMR. An intrinsically disordered loop within GCK samples multiple conformations in the unliganded state. Glucose binding and disease-associated mutations that suppress cooperativity alter the number and/or relative population of these conformational states, establishing nanosecond dynamics as part of the mechanism of GCK cooperativity.\",\n      \"method\": \"Unnatural amino acid incorporation, time-resolved fluorescence spectroscopy, 19F NMR spectroscopy\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal biophysical methods (NMR + time-resolved fluorescence + unnatural AA), structural/dynamic characterization with functional validation via disease mutations\",\n      \"pmids\": [\"32023434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Five GCK mutations (R43C, K169N, R191W, E221K, A379E) in Chinese MODY2 families show reduced enzyme activity with relative activity indexes of ~0.001–0.5 compared to wild-type (1.0), and decreased thermostability. For R250H and R275H variants, no significant difference in enzyme activity or thermal stability was detected compared to wild-type.\",\n      \"method\": \"Recombinant E. coli expression of mutant GCK, kinetic analysis, thermostability assay\",\n      \"journal\": \"Journal of diabetes investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinetic reconstitution with thermostability, single lab, no additional orthogonal methods\",\n      \"pmids\": [\"30592380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The novel gain-of-function GCK variant p.Val455Leu (V455L) significantly increases glucose affinity (S0.5: 2.4 vs 7.6 mmol/l wild-type) and shows additive susceptibility to both the endogenous activator fructose-2,6-bisphosphate and the synthetic allosteric activator RO-28-1675. GKRP binding is unimpaired for V455L, but reduced for V455M. Structural analyses implicated residue 455 in conformational rearrangements between inactive and active GCK states and in allosteric activation.\",\n      \"method\": \"Kinetic analysis of recombinant mutant GCK, allosteric activator/inhibitor assays, intracellular translocation assay, insulin secretion measurement, structural modelling\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinetics, functional cell assays, structural modelling, comparison of multiple variants, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"34532767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Hmbox1 functions as a transcriptional repressor of Gck in cardiomyocytes. Inhibition of Hmbox1 transcriptionally upregulates Gck, leading to improved mitochondrial respiration, glycolysis, reduced apoptosis, and cardioprotection after ischemia/reperfusion injury. ETS1 was identified as an upstream negative regulator of Hmbox1 transcription. These effects were confirmed by AAV9-mediated Hmbox1 knockdown and cardiomyocyte-specific Hmbox1 knockout in mice, with RNA sequencing, promoter prediction, and binding assays identifying Gck as a downstream effector.\",\n      \"method\": \"AAV9-mediated knockdown, cardiomyocyte-specific knockout (Cre-lox), RNA sequencing, promoter binding assays, Akt/mTOR/P70S6K pathway analysis, Seahorse metabolic assay, in vivo cardiac I/R injury model\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two genetic loss-of-function approaches (KD and KO) with consistent phenotype, RNA-seq, binding assays, mechanistic pathway placement, single lab\",\n      \"pmids\": [\"38708602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Silencing the Drosophila GCK orthologs Hex-A (expressed in insulin-producing cells) and Hex-C (expressed in fat body) results in MODY-2-like hyperglycemia. Hex-A is essential for insulin secretion, and Hex-A expression is required for Hex-C expression. Knockdown of either ortholog increases chromosome aberrations, reactive oxygen species, and advanced glycation end-products. Treatment with antioxidant vitamin B6 rescued chromosome aberrations, while a B6 inhibitor enhanced genomic instability, linking hyperglycemia-induced oxidative stress to DNA damage.\",\n      \"method\": \"Targeted RNAi knockdown in Drosophila, immunofluorescence for tissue expression, insulin secretion assay, ROS measurement, AGE quantification, chromosome aberration analysis, pharmacological rescue with vitamin B6\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ortholog functional studies in Drosophila with multiple readouts and pharmacological rescue; ortholog status well-supported but not mammalian GCK directly\",\n      \"pmids\": [\"33477627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Biochemical characterization of six novel MODY2-associated GCK missense mutations (Y61S, V182L, C233R, E265K, A379V, K420E) shows all produce enzymes with reduced activity to varying degrees. C233R, affecting a critical active-site residue, renders GCK with undetectable enzymatic activity. Mutation severity correlates with structural changes at the mutated position.\",\n      \"method\": \"Recombinant mutant GCK expression, enzymatic activity assay\",\n      \"journal\": \"Journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinetic reconstitution, single lab, single method\",\n      \"pmids\": [\"18322640\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Glucokinase (GCK) functions as the glucose sensor in pancreatic beta-cells by phosphorylating glucose to glucose-6-phosphate with sigmoidal kinetics (cooperative behavior) that sets the threshold for glucose-stimulated insulin secretion; its activity is allosterically regulated through conformational dynamics between inactive and active states, inhibited by glucokinase regulatory protein (GKRP) binding, and activated by endogenous fructose-2,6-bisphosphate and synthetic activators at a discrete allosteric site; disease-causing mutations impair function through reduced catalytic efficiency, decreased protein thermostability/misfolding leading to aggregation and proteasomal/lysosomal degradation, or enhanced GKRP interaction, while activating mutations increase glucose affinity and insulin secretion; in the liver, hepatic GCK expression is transcriptionally regulated by insulin and retinoids acting through a promoter RARE bound by RARα, HNF4α, and COUP-TFII, and is epigenetically suppressed by age-related promoter hypermethylation; in cardiomyocytes, GCK expression is repressed by Hmbox1 and its upregulation protects against ischemia/reperfusion injury via improved glucose metabolism.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"Glucokinase (GCK) is a glucose-phosphorylating enzyme whose kinetic and conformational properties make it the rate-setting glucose sensor of pancreatic beta-cells and a key node in hepatic glucose metabolism [#0, #8]. Its function depends on an allosteric mechanism in which an intrinsically disordered loop samples multiple conformations on the nanosecond timescale; glucose binding and disease mutations reshape the population of these states to generate cooperative (sigmoidal) kinetics, and a discrete allosteric site couples to both the endogenous activator fructose-2,6-bisphosphate and synthetic activators such as RO-28-1675 [#11, #13]. Enzyme output is modulated by binding to glucokinase regulatory protein (GKRP), and mutations can either strengthen or abolish this interaction [#1, #10, #13]. Disease-causing mutations act through three convergent routes: reduced catalytic efficiency, decreased thermostability that drives misfolding, dimerization, aggregation, and proteasomal/lysosomal degradation, or altered GKRP binding [#5, #6, #10]; thermostability rather than kinetic defect alone is the principal determinant of clinical severity in homozygous, early-onset cases [#7], whereas mutations at the allosteric activator site that increase glucose affinity cause congenital hyperinsulinism [#2, #13]. In the liver, GCK transcription is controlled by a promoter retinoic acid responsive element bound by RARalpha, HNF4alpha, and COUP-TFII, through which retinoids synergize with insulin to induce expression, and is epigenetically silenced by age-related promoter hypermethylation [#3, #4, #9]. In cardiomyocytes GCK is repressed by the transcription factor Hmbox1, and its de-repression improves glucose metabolism and protects against ischemia/reperfusion injury [#14].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that distinct GCK point mutations produce mechanistically distinct defects, separating kinetic impairment from protein instability as causes of altered insulin secretion.\",\n      \"evidence\": \"Adenoviral expression of GCK mutants in beta-HC9 cells with in vitro kinetics, Western blot, and glucose-stimulated insulin secretion\",\n      \"pmids\": [\"10455021\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural basis of instability\", \"Limited to a few mutants in one beta-cell line\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated that some MODY2 mutations impair function not by kinetics but by destabilizing protein and strengthening inhibitory GKRP binding, broadening the disease mechanism.\",\n      \"evidence\": \"Recombinant kinetics, thermal stability, and pull-down assays against GCKR and PFKFB1\",\n      \"pmids\": [\"17186219\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological consequence of enhanced GKRP binding in vivo not shown\", \"PFKFB1 interaction role left undefined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Localized activating mutations to a discrete allosteric activator site and linked increased glucose affinity to congenital hyperinsulinism.\",\n      \"evidence\": \"Kinetic characterization of recombinant activating GCK mutants\",\n      \"pmids\": [\"18450771\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of conformational activation not resolved at this stage\", \"No structural data on the activator site\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed that hepatic Gck is epigenetically silenced by age-related promoter hypermethylation, providing a non-genetic mechanism of expression control.\",\n      \"evidence\": \"Bisulphite sequencing, qPCR, kinase activity assay, and 5-Aza-CdR demethylation in rat hepatocytes\",\n      \"pmids\": [\"18496667\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Methyltransferases responsible not identified\", \"Rat liver only; human relevance not tested here\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Expanded the catalog of catalytically impairing MODY2 mutations and correlated severity with active-site structural disruption.\",\n      \"evidence\": \"Recombinant expression and enzymatic activity assays for six novel mutations\",\n      \"pmids\": [\"18322640\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single activity-assay method without orthogonal stability data\", \"No cellular validation\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined retinoids as insulin-synergizing inducers of hepatic Gck acting through RAR/RXR, independent of SREBP-1c.\",\n      \"evidence\": \"Primary rat hepatocytes, RAR/RXR pharmacological inhibition, and in vivo vitamin A deficiency/rescue\",\n      \"pmids\": [\"19173678\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct promoter element not yet mapped at this stage\", \"Did not identify all cofactors\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified protein misfolding, aggregation, and quality-control degradation as a disease mechanism for catalytically near-normal GCK-MODY mutations in the F260-L270 loop.\",\n      \"evidence\": \"Stable expression in HEK293 and MIN6 cells, pulse-chase, fractionation, and SDS-resistant dimer detection\",\n      \"pmids\": [\"22820548\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Aggregation behaviour in primary beta-cells not assessed\", \"Chaperones mediating degradation not identified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed an allosteric-site mutation can reshape the glucose-sensor conformational equilibrium rather than simply lowering activity, linking mutations to conformational state.\",\n      \"evidence\": \"Recombinant kinetics with competitive inhibitor and allosteric activator probing\",\n      \"pmids\": [\"22291974\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conformational states inferred indirectly, not directly observed\", \"No structural snapshots\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Provided an atomic-level rationale for misfolding by showing a single hydrogen-bond disruption destabilizes the F260-L271 loop to drive aggregation.\",\n      \"evidence\": \"Stable expression in HEK293/MIN6, pulse-chase, proteasome/lysosome inhibition, and structural modelling\",\n      \"pmids\": [\"24001579\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Modelled rather than experimentally determined structure of the mutant\", \"Relative proteasome vs lysosome contribution not quantified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established protein thermostability as the dominant determinant of clinical severity in homozygous early-onset disease, outweighing kinetic defects.\",\n      \"evidence\": \"Recombinant kinetics plus differential scanning fluorimetry correlated with clinical grading in 30 patients\",\n      \"pmids\": [\"25015100\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Correlation does not establish the in vivo degradation rate\", \"Heterozygous phenotype predictors not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapped the hepatic Gck RARE and its bound transcription factors, mechanistically anchoring retinoid/insulin regulation to specific cis and trans elements.\",\n      \"evidence\": \"EMSA, ChIP, adenoviral overexpression of RARalpha/HNF4alpha/COUP-TFII, and promoter mutagenesis in rat hepatocytes\",\n      \"pmids\": [\"24973045\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human promoter not directly validated\", \"RXRalpha occupancy role left unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Integrated kinetics, thermostability, and GKRP-binding measurements across many mutations to show GKRP interaction can be variably enhanced, reduced, or abolished.\",\n      \"evidence\": \"Recombinant kinetics, thermostability, and GKRP pull-down for novel and known variants\",\n      \"pmids\": [\"30257192\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular consequences of altered GKRP binding not tested\", \"Structural basis of binding changes not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Added quantitative kinetic and thermostability profiling of additional MODY2 variants, distinguishing functionally damaging from neutral substitutions.\",\n      \"evidence\": \"Recombinant E. coli expression with kinetic and thermostability assays\",\n      \"pmids\": [\"30592380\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No orthogonal cellular or binding assays\", \"Variants R250H/R275H lacked a measurable defect, leaving pathogenicity unexplained\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Directly demonstrated that nanosecond loop dynamics underlie GCK cooperativity, providing the physical mechanism of the glucose sensor.\",\n      \"evidence\": \"Unnatural amino acid incorporation, time-resolved fluorescence, and 19F NMR with disease-mutation validation\",\n      \"pmids\": [\"32023434\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics studied on isolated protein, not in cellular context\", \"Coupling of dynamics to catalytic turnover not fully quantified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked a specific activating residue to conformational rearrangement and additive responsiveness to both endogenous and synthetic allosteric activators.\",\n      \"evidence\": \"Recombinant kinetics, allosteric activator/inhibitor assays, translocation and insulin secretion assays, and structural modelling of V455L vs V455M\",\n      \"pmids\": [\"34532767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism modelled rather than directly determined\", \"Long-term clinical consequences of the variant not addressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Used Drosophila orthologs to connect GCK loss to MODY-like hyperglycemia and downstream oxidative DNA damage, extending function beyond enzyme kinetics to systemic genomic consequences.\",\n      \"evidence\": \"RNAi knockdown of Hex-A/Hex-C, insulin secretion, ROS/AGE quantification, chromosome aberration analysis, and vitamin B6 rescue\",\n      \"pmids\": [\"33477627\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ortholog model, not mammalian GCK directly\", \"Relevance of the genomic-instability axis to human disease untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified Hmbox1 as a cardiomyocyte-specific transcriptional repressor of Gck and showed GCK de-repression is cardioprotective, defining a tissue role beyond beta-cell/liver glucose sensing.\",\n      \"evidence\": \"AAV9 knockdown and cardiomyocyte-specific knockout in mice, RNA-seq, promoter binding assays, Seahorse metabolism, and in vivo I/R injury model\",\n      \"pmids\": [\"38708602\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct Hmbox1 binding to the Gck promoter detail limited\", \"Whether GCK alone is sufficient for protection not isolated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the structurally defined nanosecond dynamics, GKRP regulation, and tissue-specific transcriptional control are integrated to set glucose-sensing thresholds in vivo remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No in-cell or in-vivo measurement of GCK conformational dynamics\", \"Human hepatic/cardiac transcriptional circuitry only partially mapped\", \"Quantitative link between thermostability, degradation kinetics, and beta-cell function incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 8, 16]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 8]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 10, 13]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [0, 11, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 4, 14]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 4, 9, 14]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GCKR\",\n      \"RARA\",\n      \"RXRA\",\n      \"HNF4A\",\n      \"COUP-TFII\",\n      \"Hmbox1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}